USNA has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
USNA has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
EV-to-EBITDA is calculated as enterprise value divided by its EBITDA. As of today, Usana Health Sciences's enterprise value is $562.8 Mil. Usana Health Sciences's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 was $121.6 Mil. Therefore, Usana Health Sciences's EV-to-EBITDA for today is 4.63.
The historical rank and industry rank for Usana Health Sciences's EV-to-EBITDA or its related term are showing as below:
During the past 13 years, the highest EV-to-EBITDA of Usana Health Sciences was 16.54. The lowest was 4.21. And the median was 8.27.
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
As of today (2024-05-13), Usana Health Sciences's stock price is $46.71. Usana Health Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 was $3.210. Therefore, Usana Health Sciences's PE Ratio for today is 14.55.
The "classic" EV-to-EBITDA is much better in capturing debt and net cash than the PE Ratio.
The historical data trend for Usana Health Sciences's EV-to-EBITDA can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Usana Health Sciences Annual Data | |||||||||||||||||||||
Trend | Dec14 | Dec15 | Dec16 | Dec17 | Dec18 | Dec19 | Dec20 | Dec21 | Dec22 | Dec23 | |||||||||||
EV-to-EBITDA | Get a 7-Day Free Trial | 8.50 | 6.56 | 8.97 | 5.68 | 5.71 |
Usana Health Sciences Quarterly Data | ||||||||||||||||||||
Jun19 | Sep19 | Dec19 | Mar20 | Jun20 | Sep20 | Dec20 | Mar21 | Jun21 | Sep21 | Dec21 | Mar22 | Jun22 | Sep22 | Dec22 | Mar23 | Jun23 | Sep23 | Dec23 | Mar24 | |
EV-to-EBITDA | Get a 7-Day Free Trial | 7.34 | 7.48 | 6.80 | 5.71 | 4.91 |
For the Packaged Foods subindustry, Usana Health Sciences's EV-to-EBITDA, along with its competitors' market caps and EV-to-EBITDA data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Consumer Packaged Goods industry and Consumer Defensive sector, Usana Health Sciences's EV-to-EBITDA distribution charts can be found below:
* The bar in red indicates where Usana Health Sciences's EV-to-EBITDA falls into.
Usana Health Sciences's EV-to-EBITDA for today is calculated as:
EV-to-EBITDA | = | Enterprise Value (Today) | / | EBITDA (TTM) |
= | 562.836 | / | 121.601 | |
= | 4.63 |
Usana Health Sciences's current Enterprise Value is $562.8 Mil.
Usana Health Sciences's EBITDA for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $121.6 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Usana Health Sciences (NYSE:USNA) EV-to-EBITDA Explanation
EV-to-EBITDA is a valuation multiple used in finance and investment to measure the value of a company. This important multiple is often used in conjunction with, or as an alternative to, the PE Ratio to determine the fair market value of a company.
Usana Health Sciences's PE Ratio for today is calculated as:
PE Ratio | = | Share Price (Today) | / | Earnings per Share (Diluted) (TTM) |
= | 46.71 | / | 3.210 | |
= | 14.55 |
Usana Health Sciences's share price for today is $46.71.
Usana Health Sciences's Earnings per Share (Diluted) for the trailing twelve months (TTM) ended in Mar. 2024 adds up the quarterly data reported by the company within the most recent 12 months, which was $3.210.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Study has found that the companies with the lowest EV-to-EBITDA outperforms companies measured as cheap by other ratios such as PE Ratio.
Please read Which price ratio outperforms the enterprise multiple?
Thank you for viewing the detailed overview of Usana Health Sciences's EV-to-EBITDA provided by GuruFocus.com. Please click on the following links to see related term pages.
John Turman Fleming | director | 3838 WEST PARKWAY BLVD., SALT LAKE CITY UT 84120 |
Gilbert A Fuller | officer: CFO and Executive V.P. | 55 WANDERWOOD WAY, SANDY UT 84092 |
Frederic J Winssinger | director | 2944 N 44TH STREET, SUITE 250, PHOENIX AZ 85018 |
David Mulham Mulham | officer: Chief Field Development Office | 3838 WEST PARKWAY BLVD, SALT LAKE CITY UT 84120 |
Paul A. Jones | officer: CFO | 3838 WEST PARKWAY BLVD., SALT LAKE CITY UT 84120 |
Xia Ding | director | 3838 WEST PARKWAY BLVD., SALT LAKE CITY UT 84120 |
Daniel A. Macuga | officer: Chief Communications Officer | 3838 WEST PARKWAY BLVD., SALT LAKE CITY UT 84120 |
Jim Brown | officer: Chief Production Officer | 3838 WEST PARKWAY BLVD., SALT LAKE CITY UT 84120 |
Brent Neidig | officer: CO & Man. Dir. of China | 3838 WEST PARKWAY BLVD., WEST VALLEY CITY UT 84120 |
J Scott Nixon | director | 757 EAST SOUTH TEMPLE, SUITE 150, SALT LAKE CITY UT 84102 |
Kevin Guest | officer: E.V.P. of Marketing | 3838 WEST PARKWAY BLVD, SALT LAKE CITY UT 84120 |
Joshua Foukas | officer: Chief Legal Officer | 3838 WEST PARKWAY BLVD., SALT LAKE CITY X1 84120 |
G Doug Iiekking | officer: VP of Finance | C/O USANA HEALTH SCIENCES INC, 3838 W PARKWAY BLVD, SALT LAKE CITY UT 84120 |
Walter Noot | officer: Chief Information Officer | 3838 WEST PARKWAY BLVD, SALT LAKE CITY UT 84120 |
Robert A Sinnott | officer: Chief Scientific Officer | 400 55 WATER STREET, VANCOUVER A1 V6B1A1 |
From GuruFocus
By PRNewswire • 01-23-2024
By Business Wire • 07-10-2023
By PRNewswire • 09-06-2023
By PRNewswire • 12-04-2023
By PRNewswire • 06-28-2023
By PRNewswire • 08-16-2023
By Business Wire • 12-20-2023
By PRNewswire PRNewswire • 06-01-2023
By Business Wire • 10-09-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.